Roth Capital Downgrades Keryx Biopharmaceuticals (KERX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
FBR Capital Starts Keryx Biopharmaceuticals (KERX) at Market Perform
August 10, 2015 5:46 PM EDTFBR Capital initiates coverage on Keryx Biopharmaceuticals (NASDAQ: KERX) with a Market Perform rating and a price target of $10.00.
Analyst Christopher S. James commented, "Keryx is a commercial-stage company that markets Auryxia (ferric citrate) for the treatment of hyperphosphatemiaabnormally high phosphate levels in the bloodin chronic kidney disease... More
BTIG Cuts Keryx Biopharmaceuticals (KERX) to Sell
August 6, 2015 10:01 AM EDTBTIG earlier downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Neutral to Sell with a price target of $3.50. The change follows Q2 results. Analyst Hartaj Sing pointed out revenue weakness.
"We are downgrading Keryx from a Neutral to a Sell with a $3.50 price target after the... More
